NasdaqCM - Delayed Quote • USD
Aligos Therapeutics, Inc. (ALGS)
At close: May 31 at 4:00 PM EDT
After hours: May 31 at 7:56 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.16 | -0.17 | -0.74 | -0.63 |
| Low Estimate | -0.16 | -0.17 | -0.75 | -0.71 |
| High Estimate | -0.16 | -0.17 | -0.73 | -0.55 |
| Year Ago EPS | -0.43 | -0.41 | -1.36 | -0.74 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | 990k | -- |
| Low Estimate | -- | -- | 990k | -- |
| High Estimate | -- | -- | 1M | -- |
| Year Ago Sales | 6.89M | 2.5M | 9.34M | 990k |
| Sales Growth (year/est) | -- | -- | -89.40% | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.49 | -0.47 | -0.27 | -0.19 |
| EPS Actual | -0.43 | -0.41 | -0.22 | -0.22 |
| Difference | 0.06 | 0.06 | 0.05 | -0.03 |
| Surprise % | 12.20% | 12.80% | 18.50% | -15.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.16 | -0.17 | -0.74 | -0.63 |
| 7 Days Ago | -0.16 | -0.17 | -0.74 | -0.63 |
| 30 Days Ago | -0.21 | -0.21 | -0.83 | -0.82 |
| 60 Days Ago | -0.21 | -0.21 | -0.83 | -0.82 |
| 90 Days Ago | -0.26 | -0.25 | -1.04 | -1.06 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 2 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ALGS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 62.80% | -- | -- | 7.70% |
| Next Qtr. | 58.50% | -- | -- | 10.10% |
| Current Year | 45.60% | -- | -- | 4.60% |
| Next Year | 14.90% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.29% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Piper Sandler: Overweight | 1/17/2023 |
| Upgrade | Piper Sandler: Neutral to Overweight | 1/6/2023 |
| Upgrade | Jefferies: Hold to Buy | 1/6/2023 |
| Maintains | SVB Leerink: Market Perform | 11/3/2022 |
| Downgrade | SVB Leerink: Outperform to Market Perform | 5/5/2022 |
| Maintains | SVB Leerink: Outperform | 3/23/2022 |
Related Tickers
ASMB Assembly Biosciences, Inc.
15.15
+1.95%
SPRO Spero Therapeutics, Inc.
1.4200
0.00%
GLPG.AS Galapagos NV
25.74
+1.82%
IKNA Ikena Oncology, Inc.
1.7700
-1.12%
CLRB Cellectar Biosciences, Inc.
3.0900
+1.64%
BOLT Bolt Biotherapeutics, Inc.
0.7567
-0.32%
SYBX Synlogic, Inc.
1.5600
-0.64%
TBPH Theravance Biopharma, Inc.
8.62
+1.53%
ALVR AlloVir, Inc.
0.7549
+1.00%
GLPG Galapagos NV
27.82
+1.31%